ArticleDigestive diseases and sciences2026
Mechanistic Investigation of FBXW11-Mediated Ubiquitination and Degradation of HIC1 in Regulating IRF1 Transcription and Accelerating Acute Pancreatitis Progression.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study aims to elucidate the molecular mechanism by which F-box and WD repeat domain-containing 11 (FBXW11) promotes the progression of acute pancreatitis (AP) through ubiquitination-mediated degradation of Hypermethylated in Cancer 1 (HIC1), thereby enhancing Interferon Regulatory Factor 1 (IRF1) transcription.
methodsA murine model of AP was generated by intraperitoneal cerulein administration, after which pancreatic tissues were harvested for RNA sequencing (RNA-seq). Differentially expressed genes (DEGs) were screened, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Potential key regulators were identified using least absolute shrinkage and selection operator (LASSO) regression and random forest algorithms. Co-immunoprecipitation (Co-IP), ubiquitination, and chromatin immunoprecipitation (ChIP) assays were used to verify protein interactions and regulatory effects among FBXW11, HIC1, and IRF1. The impact of the FBXW11/HIC1 axis on AP-specific cellular phenotypes was assessed using qPCR, Western blot, immunofluorescence, CCK-8, Enzyme-Linked Immunosorbent Assay (ELISA), and flow cytometry. Finally, the role of the FBXW11/HIC1/IRF1 axis in AP was validated in vivo using a mouse model.
resultsRNA-seq identified 3489 DEGs significantly associated with immune regulation and ferroptosis pathways. FBXW11 emerged as a central regulator that promotes HIC1 ubiquitination and degradation, thereby releasing IRF1 from transcriptional suppression. Silencing of FBXW11 or overexpression of HIC1 markedly decreased inflammatory cytokines (IL-6, TNF-α, and IL-1β) and reduced cellular apoptosis. In vivo experiments showed that inhibiting FBXW11 expression significantly alleviated AP symptoms in mice, with marked reductions in pancreatic tissue damage and inflammatory response.
conclusionFBXW11 promotes the progression of AP by enhancing IRF1 transcription through the ubiquitination-mediated degradation of HIC1. Inhibition of FBXW11 or HIC1 effectively reduces the production of inflammatory cytokines and decreases cell apoptosis, thereby alleviating the symptoms of AP.
Indexed as
Identifiers
41288880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.